For the Inventor, By the Inventor

Enter assignee name

Schlieren, Switzerland

Esbatech, an Alcon Biomedical Research Unit LLC

USPTO Granted Patents = 36

CIPO Patents = 46

EPO Patents = 16

Forward Citations = 182

Loading Chart...

Loading Chart...

45 inventors (with patents filed for the assignee):

David M Urech (27 out of 47 patents)

Leonardo Borras (16 out of 25 patents)

Alcide Barberis (8 out of 22 patents)

4. Adrian Auf Der Maur (8 out of 17 patents)

5. Stefan Ewert (7 out of 15 patents)

6. Dominik Escher (6 out of 14 patents)

7. Tea Gunde (5 out of 24 patents)

8. Valerie Hulmann-Cottier (5 out of 5 patents)

9. Peter Lichtlen (5 out of 9 patents)

10. Kathrin Tissot (3 out of 11 patents)

11. Robert Gurny (2 out of 21 patents)

12. Lutz Asmus (2 out of 3 patents)

13. Michael Möller (2 out of 3 patents)

14. John P A Grimshaw (2 out of 2 patents)

15. Esther Furrer (1 out of 1 patent)

36 patents: Sort by Forward Citations

1. 10221237 - Solubility optimization of immunobinders (2019-03-05),

2. 10125186 - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same (2018-11-13),

3. 10100111 - Stable and soluble antibodies inhibiting TNF alpha (2018-10-16),

4. 10093726 - Protein sustained-release injectable formulation (2018-10-09),

5. 10087244 - Humanization of rabbit antibodies using a universal antibody framework (2018-10-02),

6. 9938336 - Sequence based engineering and optimization of single chain antibodies (2018-04-10),

7. 9908945 - Sequence based engineering and optimization of single chain antibodies (2018-03-06),

8. 9908940 - Humanized immunobinders of cell-surface antigens (2018-03-06),

9. 9873737 - Stable and soluble antibodies inhibiting VEGF (2018-01-23),

10. 9873736 - Protein sustained-release injectable formulation (2018-01-23),

11. 9803027 - Method for decreasing immunogenicity (2017-10-31),

12. 9683034 - Stable and soluble antibodies inhibiting TNFα (2017-06-20),

13. 9593161 - Humanization of rabbit antibodies using a universal antibody framework (2017-03-14),

14. 9556265 - Solubility optimization of immunobinders (2017-01-31),

15. 9518108 - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same (2016-12-13),

ESBATech, an Alcon Biomedical Research Unit LLC, is a leading global biopharmaceutical company specializing in the research, development, and commercialization of innovative therapies. With a focus on ophthalmology, ESBATech aims to improve the lives of patients by pioneering cutting-edge solutions for vision-related conditions. Visit our website for more information.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

36 Patents

#2 in Schlieren

#373 in Switzerland

#18,140 in the World

Schlieren, Switzerland

Esbatech, an Alcon Biomedical Research Unit LLC

Forward Citations = 182

45 inventors:

David M Urech (27 out of 47 patents)

Leonardo Borras (16 out of 25 patents)

Alcide Barberis (8 out of 22 patents)

4. Adrian Auf Der Maur (8 out of 17 patents)

5. Stefan Ewert (7 out of 15 patents)

Please report any incorrect information to support@idiyas.com

Loading…